Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback